BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tombling BJ, Zhang Y, Huang YH, Craik DJ, Wang CK. The emerging landscape of peptide-based inhibitors of PCSK9. Atherosclerosis 2021;330:52-60. [PMID: 34246818 DOI: 10.1016/j.atherosclerosis.2021.06.903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ahamad S, Bhat SA. Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. J Med Chem 2022;65:15513-39. [PMID: 36446632 DOI: 10.1021/acs.jmedchem.2c01290] [Reference Citation Analysis]
2 Doolan JA, Williams GT, Hilton KLF, Chaudhari R, Fossey JS, Goult BT, Hiscock JR. Advancements in antimicrobial nanoscale materials and self-assembling systems. Chem Soc Rev 2022;51:8696-755. [PMID: 36190355 DOI: 10.1039/d1cs00915j] [Reference Citation Analysis]
3 Chen R, Zhao H, Zhou J, Wang Y, Li J, Zhao X, Li N, Liu C, Zhou P, Chen Y, Song L, Yan H. Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study. Biomolecules 2022;12. [PMID: 36291690 DOI: 10.3390/biom12101482] [Reference Citation Analysis]
4 Zhang Y, Wang L, Tombling BJ, Lammi C, Huang Y, Li Y, Bartolomei M, Hong B, Craik DJ, Wang CK. Improving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide. J Am Chem Soc . [DOI: 10.1021/jacs.2c08029] [Reference Citation Analysis]
5 Salekeen R, Haider AN, Akhter F, Billah MM, Islam ME, Didarul Islam KM. Lipid oxidation in pathophysiology of atherosclerosis: Current understanding and therapeutic strategies. International Journal of Cardiology Cardiovascular Risk and Prevention 2022;14:200143. [DOI: 10.1016/j.ijcrp.2022.200143] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Hackam DG, Hegele RA. Lipid-Modifying Therapies and Stroke Prevention. Curr Neurol Neurosci Rep 2022. [PMID: 35554824 DOI: 10.1007/s11910-022-01197-4] [Reference Citation Analysis]
7 Seidah NG, Prat A. The multifaceted biology of PCSK9. Endocr Rev 2021:bnab035. [PMID: 34626468 DOI: 10.1210/endrev/bnab035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]